지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Cancer immunotherapy has come a long way since William Coley observed that a mixture of killed bacteria, or Coley’s toxin, inducedtumor regression. However, enthusiasm for cancer immunotherapy has changed to skepticism over recent decades due to itslack of efficacy, inconsistency, and significant toxicity. Of course, much of that skepticism was the result of a lack of understandingof the immune system. The recent expansion of our understanding of immunity and immune system and the success of new cancerimmunotherapies has raised hope that we can treat cancer effectively via immunotherapy or combination approach using immunotherapyand other cancer therapies. Indeed, there is no doubt that cancer immunotherapy is experiencing a renaissance. Here,I will briefly review the current status of various immunotherapies, including cytokine therapy, antibody therapy, cancer vaccines,and adoptive cell therapy, and then I will summarize the results of recent clinical trials using anti-immune checkpoint monoclonalantibodies.
목차
등록된 정보가 없습니다.
참고문헌 (23)
참고문헌 신청
Brahmer JR / 2012 / Safety and activity of anti-PD-L1 antibody in patients with advanced cancer / N Engl J Med 366 : 2455 ~ 2465
Cheever MA / 2011 / PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine / Clin Cancer Res 17 : 3520 ~ 3526
Crosbie EJ / 2007 / Cervarix: a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer / Expert Opin Biol
Grossardt C / 2013 / Granulocytemacrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine / Hum Gene Ther 24 : 644 ~ 654
Hamid O / 2013 / Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM): American
Cheever MA / 2011 / PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine / Clin Cancer Res 17 : 3520 ~ 3526
Crosbie EJ / 2007 / Cervarix: a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer / Expert Opin Biol
Grossardt C / 2013 / Granulocytemacrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine / Hum Gene Ther 24 : 644 ~ 654
Hamid O / 2013 / Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM): American
이 논문의 저자 정보
최근 본 자료
댓글(0)
0